Aurobindo Pharma entered the rapidly growing biologics contract manufacturing market with the inauguration of TheraNym, a dedicated biologics Contract Manufacturing Organization (CMO). Located in Borapatla near Hyderabad, the state-of-the-art facility marks a significant milestone in the company’s strategic expansion into advanced biologics manufacturing. The facility is expected to strengthen India’s position in the global biologics supply chain while supporting increasing worldwide demand for biologic medicines.
TheraNym Positioned Among India’s Largest Biologics CMOs
TheraNym has been designed as one of India’s largest dedicated biologics contract manufacturing facilities. The plant has already secured a major endorsement from global pharmaceutical leader MSD (known as Merck & Co. in the United States and Canada), which will serve as the facility’s anchor customer. The collaboration highlights growing confidence in India’s capabilities to deliver high-quality biologics manufacturing services that meet international standards.
Strategic Expansion into a High-Growth Biologics Market
With the launch of TheraNym, Aurobindo Pharma is expanding beyond its traditional pharmaceutical manufacturing business and entering a segment experiencing strong global growth. Satakarni Makkapati, CEO – Biologics and Director, Aurobindo Pharma Limited, described the facility as a landmark achievement for both the company and India’s biopharmaceutical sector. He stated that TheraNym represents a defining moment in large-scale biologics manufacturing in India. Built to meet the highest international standards, the facility is designed to support the supply chains of leading global pharmaceutical companies while enabling broader access to life-saving biologic therapies worldwide.
Advanced Manufacturing Infrastructure and Global Compliance
The TheraNym facility is equipped with advanced manufacturing and quality systems designed to meet stringent global regulatory requirements. Key infrastructure includes 15 KL bioreactor capacity, advanced downstream processing suites, aseptic fill-finish manufacturing capabilities, and modern quality control and analytical laboratories. The facility has been developed in alignment with international regulatory expectations, ensuring high standards of product quality, safety, and operational reliability.
MSD Partnership Strengthens Global Supply Chain
MSD’s partnership with TheraNym underscores the strategic importance of the facility in supporting global biologics production. Dave Maraldo, Executive Vice President and President of MSD Manufacturing Division, said the collaboration reflects a shared commitment to improving global access to critical biologic medicines. According to Maraldo, the partnership adds valuable manufacturing capacity and technical capabilities to MSD’s supply chain while helping ensure a compliant, reliable, and uninterrupted supply of biologic products to patients worldwide.
Supporting Global Access to Biologic Medicines
As demand for biologics continues to grow across therapeutic areas such as oncology, immunology, and chronic disease management, manufacturing capacity has become a critical factor in ensuring timely patient access. Through TheraNym, Aurobindo Pharma aims to provide scalable, cost-effective, and globally compliant manufacturing solutions that help pharmaceutical companies accelerate product availability while maintaining quality standards.
Strengthening India’s Position in Biopharmaceutical Manufacturing
The launch of TheraNym reinforces India’s growing role as a global hub for biopharmaceutical innovation and manufacturing. By investing in advanced biologics infrastructure and forming strategic partnerships with global pharmaceutical companies, Aurobindo Pharma is positioning itself to capitalize on the expanding biologics market while contributing to improved healthcare access worldwide. As reported by cnbctv18.com, the facility represents a significant step in the company’s long-term growth strategy and its ambition to become a key player in the global biologics manufacturing ecosystem.
